Payment overview · 2025
General Payments
$250.23
12 reported records · 4 companies
Healthcare provider profile · identity verified
Ramon L. Rivera Schneider, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ARECIBO, PR · NPI 1962585521
Verified facts
What the public records show
CMS Open Payments records show Ramon L. Rivera Schneider, M.D. received $250.23 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 71.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 411 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $178.76 | 71.4% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $24.08 | 9.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.85 | 9.5% | 1 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $23.54 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $250.23 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $123.20 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.56 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
411 | 54 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1158 | 160 |
| Famotidine | Famotidine | 725 | 135 |
| Atorvastatin Calcium | Atorvastatin Calcium | 543 | 164 |
| Pantoprazole Sodium | Pantoprazole Sodium | 529 | 83 |
| Alendronate Sodium | Alendronate Sodium | 513 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 467 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 423 | 116 |
| Synthroid | Levothyroxine Sodium | 411 | 54 |
| Montelukast Sodium | Montelukast Sodium | 399 | 64 |
| Omeprazole | Omeprazole | 367 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 340 | 48 |
| Clonazepam | Clonazepam | 314 | 50 |
| Metformin Hcl | Metformin Hcl | 286 | 77 |
| Losartan Potassium | Losartan Potassium | 285 | 90 |
| Clopidogrel | Clopidogrel Bisulfate | 275 | 47 |
| Lisinopril | Lisinopril | 258 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 74 |
| Sertraline Hcl | Sertraline Hcl | 221 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 60 |
| Simvastatin | Simvastatin | 200 | 56 |
| Carvedilol | Carvedilol | 155 | 50 |
| Finasteride | Finasteride | 143 | 23 |
| Glipizide | Glipizide | 142 | 39 |
| Donepezil Hcl | Donepezil Hcl | 139 | 27 |
| Prednisone | Prednisone | 129 | 83 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 71 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 119 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 116 | 43 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 116 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 31 |
| Trazodone Hcl | Trazodone Hcl | 103 | 20 |
| Valsartan | Valsartan | 100 | 30 |
| Tradjenta | Linagliptin | 99 | 13 |
| Farxiga | Dapagliflozin Propanediol | 97 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 94 | 18 |
| Cilostazol | Cilostazol | 93 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 17 |
| Pentoxifylline | Pentoxifylline | 92 | 13 |
| Januvia | Sitagliptin Phosphate | 88 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 85 | 31 |
| Glimepiride | Glimepiride | 82 | 26 |
| Azithromycin | Azithromycin | 77 | 68 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 74 | 22 |
| Lorazepam | Lorazepam | 74 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 72 | 19 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 69 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 67 | 19 |
| Baclofen | Baclofen | 63 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 63 | 18 |
| Levetiracetam | Levetiracetam | 63 | suppressed |
| Spironolactone | Spironolactone | 63 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 16 |
| Metformin Hcl Er | Metformin Hcl | 60 | 15 |
| Naproxen | Naproxen | 60 | 31 |
| Memantine Hcl | Memantine Hcl | 58 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 11 |
| Irbesartan | Irbesartan | 51 | 15 |
| Alprazolam | Alprazolam | 50 | suppressed |
| Bumetanide | Bumetanide | 45 | 19 |
| Nabumetone | Nabumetone | 44 | 19 |
| Temazepam | Temazepam | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 42 | suppressed |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 32 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 38 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 38 | 11 |
| Levofloxacin | Levofloxacin | 37 | 34 |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 35 | suppressed |
| Furosemide | Furosemide | 34 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 25 |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 18 |
| Fluconazole | Fluconazole | 29 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | 11 |
| Nifedipine Er | Nifedipine | 29 | 11 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 28 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Cefadroxil | Cefadroxil | 24 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | 16 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 23 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 19 |
| Propafenone Hcl | Propafenone Hcl | 21 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 18 | suppressed |
| Rytary | Carbidopa/Levodopa | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Levoxyl | Levothyroxine Sodium | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Estazolam | Estazolam | 12 | suppressed |
| Bicillin L-A | Penicillin G Benzathine | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $250.23 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ELIQUIS, FARXIGA, LOKELMA, MOUNJARO, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error